On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach (Q39112394)

9 September 2017

title

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach (English)

1 reference

9 September 2017

1 reference

Nahor Haddish-Berhane

1

1 reference

9 September 2017

Dhaval K Shah

2

1 reference

9 September 2017

Dangshe Ma

3

1 reference

9 September 2017

Mauricio Leal

4

1 reference

9 September 2017

Hans-Peter Gerber

5

1 reference

9 September 2017

Puja Sapra

6

1 reference

9 September 2017

Hugh A Barton

7

1 reference

9 September 2017

Alison M Betts

8

1 reference

9 September 2017

publication date

10 August 2013

1 reference

Journal of Pharmacokinetics and Pharmacodynamics

9 September 2017

published in

1 reference

9 September 2017

volume

40

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

557-571

1 reference

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Predicting the active doses in humans from animal studies: a novel approach in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Interspecies scaling of therapeutic monoclonal antibodies: initial look

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Prediction of Exposure–Response Relationships to Support First-in-Human Study Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Mathematical modeling of liver metastases tumour growth and control with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10928-013-9329-X

Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved

21 January 2018

1 reference

12 December 2020

Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro

1 reference

12 December 2020

A guide to the new ARENA/OLAW IACUC guidebook

1 reference

12 December 2020

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

1 reference

12 December 2020

10.1007/S10928-013-9329-X

Identifiers

DOI

1 reference

9 September 2017

1 reference